Epoxyeicosatrienoic acids (EETs) are synthesized in astrocytes, and inhibitors of soluble epoxide hydrolase (sEH), which hydrolyzes EETs, reduce infarct volume in ischemic stroke. Astrocytes can release protective neurotrophic factors, such as vascular endothelial growth factor (VEGF). We found that addition of sEH inhibitors to rat cultured astrocytes immediately after oxygen-glucose deprivation (OGD) markedly increased VEGF concentration in the medium 48 h later and the effect was blocked by an EET antagonist. The sEH inhibitors increased EET concentrations to levels capable of increasing VEGF. When the sEH inhibitors were removed from the medium at 48 h, the increase in VEGF persisted for an additional 48 h. Neurons exposed to OGD and subsequently to astrocyte medium previously conditioned with OGD plus sEH inhibitors showed increased phosphorylation of their VEGF receptor-2, less TUNEL staining, and increased phosphorylation of Akt, which was blocked by a VEGF receptor-2 antagonist. Our findings indicate that sEH inhibitors, applied to cultured astrocytes after an ischemia-like insult, can increase VEGF secretion. The released VEGF then enhances Aktenabled cell survival signaling in neurons through activation of VEGF receptor-2 leading to less neuronal cell death. These results suggest a new strategy by which astrocytes can be leveraged to support neuroprotection.
Astrocytes protect neurons from stroke by a variety of mechanisms, such as buffering the changes in extracellular ions, importing released glutamate, synthesizing glutathione, and promoting vasodilation (Ouyang et al. 2014) . Astrocytes can also serve as a source of trophic factors that protect neurons and promote neurogenesis and angiogenesis (Newton et al. 2013; Oliveira et al. 2013) .
Within astrocytes, epoxyeicosatrienoic acids (EETs) derived from the epoxygenation of arachidonic acid have emerged as signaling molecules that facilitate openings of TRPV4 and calcium-activated potassium (K Ca ) channels (Gebremedhin et al. 2003; Yamaura et al. 2006; Higashimori et al. 2010; Dunn et al. 2013) . Exposure of cultured astrocytes to hypoxia or glutamate increases the synthesis and release of EETs (Nithipatikom et al. 2001; Yamaura et al. 2006) , suggesting that they may be functionally important under conditions of ischemia. EETs are hydrolyzed by soluble epoxide hydrolase (sEH) to corresponding 1,2-dihydroxyeicosatrienoic acids (Morisseau and Hammock 2013) . In vivo, inhibition of sEH or gene deletion of sEH reduces infarct volume after transient middle cerebral artery occlusion Shaik et al. 2013) . In these studies, sEH null mice have less severe reduction in intraischemic cerebral blood flow, but other mechanisms are also likely to contribute to the reduction in infarct volume. Administration of an sEH inhibitor at the start of reperfusion following transient focal ischemia also reduces infarct volume (Zhang et al. 2007) , suggesting that EETs play a protective role after ischemia.
In this study, in order to identify other neuroprotective mechanisms that are independent of blood flow, we exposed primary astrocyte cultures to oxygen-glucose deprivation (OGD) and then treated them with sEH inhibitors after reoxygenation. We focused on administration after reoxygenation because treatment after reperfusion is more clinically relevant, and oxygen-dependent formation of epoxides is more likely to occur after reoxygenation. We also investigated the effect of treating OGD-exposed primary neuronal cultures with medium from astrocytes previously conditioned with OGD and sEH inhibitors. We focused on astrocyte release of vascular endothelial growth factor (VEGF) because astrocytes release VEGF under hypoxic conditions (Sinor et al. 1998; Schmid-Brunclik et al. 2008) , sEH inhibitors can promote VEGF release in other tissue (Panigrahy et al. 2013) and VEGF can exert pro-survival effects in neurons and may promote reparative mechanisms through its angiogenic effects (Shibuya 2009; Sanchez et al. 2010; Li et al. 2012) . Two main hypotheses were tested. First, administration of sEH inhibitors to astrocytes after OGD increases the release of VEGF into the medium by a mechanism that requires the action of EETs. Second, medium derived from astrocytes that are treated with sEH inhibitors after OGD augments the pro-survival phosphorylation of Akt in OGD-exposed neurons. We also determined whether this augmentation requires activation of neuronal VEGF receptor-2 (VEGFR2), the primary receptor mediating neuronal protection by VEGF (Hao and Rockwell 2013) . Throughout the studies, two structurally distinct sEH inhibitors were used: 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU) (Rose et al. 2010; Ulu et al. 2012 ) and trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) (Hwang et al. 2007 ).
Materials and methods

Animals
Timed-pregnant Sprague-Dawley rats (14-15 days of gestation) were purchased from Charles River (Wilmington, MA, USA) and housed at the Johns Hopkins University animal facilities. Primary cultured astrocytes were prepared from 1-day post-natal rat pups, and neurons were prepared from E15 rat embryos. All studies were performed in accordance with National Institutes of Health Guidelines for the Care and Use of Laboratory Animals, and protocols were approved by the Johns Hopkins University Animal Care and Use Committee.
Chemicals
The sEH inhibitors TPPU and t-AUCB were synthesized according to published procedures (Hwang et al. 2007; Rose et al. 2010) . Both agents were dissolved in dimethyl sulfoxide (DMSO that was also used as a vehicle control) as 10 mM stock solutions. They were used at final concentrations of 0.1, 1, 3, 10, 30, and 100 lM. The EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) and authentic 14,15-EET were purchased from Cayman Chemical Company (Ann Arbor, MI, USA), dissolved in DMSO, and used at a final concentration of 100 and 30 lM, respectively.
Astrocyte cultures
Primary cultures of astrocytes were generated as described (McCarthy and de Vellis 1980) . Briefly, cerebral cortices were minced and dissociated with 0.25 mg/mL trypsin-EDTA for 15 min at 37°C and then rinsed with Dulbecco's Modified Eagle Medium (DMEM)/Nutrient Mixture F-12 containing 10% fetal bovine serum (FBS; Invitrogen, Grand Island, NY, USA). Tissue pieces were triturated by a pipette and then passed through a 40-lm mesh strainer (BD Falcon, Franklin Lakes, NJ, USA). Isolated cells were then suspended in DMEM/F12 with 10% FBS and 1% penicillin/ streptomycin, plated on 10 lg/mL poly-D-lysine-coated 75 cm 2 flasks (Corning, Corning, NY, USA) at a density of 1 9 10 6 cells/ cm 2 , and incubated at 37°C in a 95%/5% mixture of atmospheric air and CO 2 . At day in vitro (DIV) 8, glial cultures were shaken for 18 h at 260 rpm in a temperature-controlled incubator to dislodge oligodendrocytes and microglial cells. The remaining cells were maintained for an additional 3 days, detached with 0.25 mg/mL trypsin-EDTA, and seeded in 24-well plates. The cultured astrocytes were used for experiments at DIV 15. Immunocytochemical staining of the cell cultures with an antibody specific to glial fibrillary acidic protein (GFAP) showed that > 95% of cells were GFAP-positive astrocytes. The density of confluent astrocytes was 1 9 10 5 cells/cm 2 . The number of dead astrocytes was determined by staining with propidium iodide (PI, Invitrogen, Waltham, MA, USA), which enters the nuclei of dead cells and co-localizes with the nuclear stain, 4',6-diamidino-2-phenylindole DAPI. Astrocytes were fixed with 4% paraformaldehyde for 30 min at 24°C after which the cells were covered with methanol for 5 min and immunostained for GFAP. Then they were washed and equilibrated briefly in 2X SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0) and incubated in 100 lg/mL DNase-free RNase in 2X SSC for 20 min at 37°C. After rinsing three times for 1 min in 2X SSC, the cells were incubated with 1 lM PI at 24°C for 10 min. The working solution of 1 lM PI was made by diluting the 1 mg/mL (1.5 mM) stock solution 1 : 1500 in 2X SSC. Finally, the cells were washed three times with 2X SSC, and then observed under a fluorescence microscope.
To test the effect of sEH inhibitors on VEGF expression and secretion, we allocated primary astrocytes into three groups: normoxia (without OGD or sEH inhibitor treatment), ODG plus DMSO vehicle (OGD and then 0.1% DMSO treatment), and OGD plus sEH inhibitor (OGD and then sEH inhibitor treatment). Because induction of VEGF after ischemia is unlikely to be immediate, we extended the inhibitor treatment for 48 h after OGD to assure that the inhibitor was present during the period of potential induction.
Neuronal cultures
Primary neuronal cultures were prepared from cerebral cortices of E15 Sprague-Dawley rat embryos. Following the same dissociation protocol described for astrocyte cultures, we plated cells at a low density (1 9 10 5 cells/cm 2 ) on poly-D-lysine-coated 12-mm coverslips for immunocytochemistry, and at a higher density (5 9 10 5 cells/cm 2 ) in coated six-well plates for western blot analysis. The cells were cultured initially in DMEM/F12 containing 10% FBS. After 4 h, the medium was replaced with Neurobasal medium supplemented with B27 (NB/B27), L-glutamine, and 1% penicillin/streptomycin (Invitrogen). At DIV 4, one-half of the medium in each well was replaced, and 2 lM cytosine arabinoside was added to prevent nonneuronal proliferation. Experiments were performed on cells at DIV 8. The cultures contained > 95% neurons as demonstrated by immunocytochemical staining for microtubule associated protein 2 (MAP2).
Oxygen-glucose deprivation
The OGD model was performed as previously described (Huang et al. 2008) . Briefly, cells were washed twice, incubated in glucosefree DMEM (Invitrogen), and then placed in a hypoxic incubator filled with a gas mixture of 95% N 2 and 5% CO 2 at 37°C for the designated period (6 h for astrocytes, 1 h for neurons). After OGD, cultures were returned to standard medium and reoxygenated in a normoxic incubator with 5% CO 2 /95% air.
Drug administration
Vehicle (0.1% DMSO), TPPU, or t-AUCB was added to astrocytes in oxygenated, glucose-containing DMEM/F12 immediately after 6 h of OGD. TPPU and t-AUCB were used at final concentrations of 0.1, 1, 3, 10, 30, and 100 lM. The cells were left in culture for an additional 48 h, and then both cells and medium were processed for VEGF ELISA assay as described below. To test the role of EETs in TPPU/t-AUCB-induced VEGF secretion, we added the EET antagonist 14,15-EEZE (100 lM) in combination with TPPU or t-AUCB (100 lM) or authentic 14,15-EET (0.1-30 lM) during the 48 h of reoxygenation.
Liquid chromatographic-mass spectrometric (LC-MS) measurements of EETs
To determine changes in the production levels of cytochrome P450 (CYP) epoxygenase-derived EETs, cultured astrocytes were treated with 40 lM arachidonic acid in potassium phosphate buffer (0.1 M, pH 7.4) containing the NADPH-generating system (20 mM isocitrate and 0.1 units/mL isocitrate dehydrogenase), 1 mM EDTA, 10 mM MgCl 2 . The normoxia group was incubated with media containing 5.6 mM glucose for the entire course of the experiment, whereas the remaining groups underwent 6 h of OGD. Following OGD, the media was replaced with culture media containing 5.6 mM glucose and either 0.1% DMSO or the sEH inhibitors TPPU (100 lM) and t-AUCB (100 lM). Following 24 h of reoxygenation, the media was collected and kept on ice. The samples were spiked with 2 ng deuterated 2H 8 -EETs as an internal standard. The samples were acidified to pH 3.5 and extracted twice with 3 mL of diethyl ether with gentle vortexing for 1 min, and then centrifuged at 5000 g for 5 min. The diethyl ether layer was then transferred to a clean 10-mL glass centrifuge tube and dried under a flow of nitrogen gas. The dried samples were then reconstituted in 200 lL of acetonitrile for analysis by LC-MS in the negative ion mode. For quantitative measurements, the m/z 319 and 327 ions were used for EETs and [2H8] EETs respectively. The standard curves were typically constructed over the range of 1-100 pg per injection. The concentrations of the four regioisomers of EETs were calculated by comparing the ratios of their peak areas to standard curves as previously described (Nithipatikom et al. 2001 ) and expressed as concentration per unit volume of astrocyte media.
Co-culture
For co-culture experiments, primary astrocytes were seeded at a density of 1 9 10 5 cells/cm 2 on filter membrane (0.4 lm pores)
tissue culture inserts in 24-and 6-well plates (Corning). These astrocytes were exposed to 6-h OGD and reoxygenated for 48 h with or without sEH inhibitor TPPU/t-AUCB (100 lM). After the OGD/reoxygenation period, the astrocyte medium was replaced with NB/B27 medium for an additional 24 h to generate conditioned medium compatible with the neuronal medium. The conditioned medium was processed for VEGF ELISA assay or co-culture as described below. Primary neurons were seeded on 12-mm coverslips in 24-well and 6-well plates as described above; at DIV 8, neurons were subjected to 1 h OGD. At the time of reoxygenation, the neuron-covered coverslips were placed under the inserts holding OGD/reoxygenation-stimulated astrocytes that had been grown for 24 h in NB/B27. The neurons were co-cultured with astrocytes on the transwell membranes for 24 h, after which cell lysates of neurons in the six-well plates were collected for western blot analysis, and neurons on the coverslips were fixed and processed for assessment of neuronal cell death as described below.
ELISA Culture medium of astrocytes was collected after treatment, and cells were lysed in RIPA lysis buffer (Thermo Scientific, Waltham, MA, USA). VEGF concentrations in the cell lysate and culture medium were measured in duplicate with VEGF ELISA kits (ab100786; ab100787, Abcam, Cambridge, UK) according to the manufacturer's instructions, and the levels were detected with a microplate reader at a wavelength of 450 nm. Measurements of VEGF concentrations in the astrocyte medium included: (i) following 48-h exposure to 100 lM TPPU or t-AUCB in normoxic astrocytes not subjected to OGD, (ii) after OGD and 48-h exposure to vehicle or 0.1, 1, 3, 10, 30, and 100 lM TPPU or t-AUCB, (iii) after OGD and 48-h exposure to vehicle, 100 lM TPPU, 100 lM t-AUCB, or 100 lM 14,15-EEZE plus TPPU or t-AUCB, (iv) in response to addition of 0.1, 1, 10, and 30 lM 14,15-EET to the astrocyte medium for 48 h after OGD, (v) evaluation of the time course of VEGF over 48 h after switching the astrocyte medium to NB/B27 following previous treatment with OGD and either vehicle or 100 lM TPPU, and (vi) after switching the astrocyte medium to NB/B27 following previous treatment with OGD and vehicle, 100 lM TPPU, or 100 lM t-AUCB.
In situ labeling of fragmented DNA Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nickend labeling (TUNEL) staining was performed according to the manufacturer's instructions (In situ cell death detection kit, Roche, Mannheim, Germany). Briefly, neurons grown on coverslips and subjected to OGD as described above were fixed for 30 min in 4% paraformaldehyde and blocked with 3% H 2 O 2 in methanol. After three washes in phosphate-buffered saline (PBS), the cells were permeabilized with 0.1% Triton X-100 for 2 min on ice, and then incubated for 60 min in a 37°C humidified chamber with TUNEL reaction buffer containing TdT enzyme and fluorescein-labeled nucleotide mixture. The reaction was terminated in PBS. In the second step, the cells were incubated with antibody against MAP2 (ab11267, 1 : 200, Abcam) at 4°C overnight and then with Alexa Fluor 568-conjugated goat anti-mouse IgG antibody (A-11004, 1 : 400, Invitrogen) for 1 h at 24°C. Coverslips were washed 3 9 5 min with PBS between each step. Coverslips were stained with DAPI and mounted on glass microscope slides (Vector Laboratories, Burlingame, CA, USA). Fluorescence microscopy was performed and the number of apoptotic neurons was determined by counting the MAP2/TUNEL double-stained cells in three different fields of view on each coverslip.
Western blot analysis
Neurons grown on six-well plates and subjected to treatment described above were lysed in RIPA lysis buffer (Thermo Scientific). Protein concentrations were determined with a bicinchoninic acid protein assay kit (Thermo Scientific) according to the manufacturer's instructions. Equal amounts of each protein sample (total protein extract, 30 lg) were separated by electrophoresis in 4-15% SDS-polyacrylamide gels (Mini-PROTEAN TGX precast gel, Bio-Rad, Hercules, CA, USA) and transferred to polyvinylidene fluoride membranes. After being blocked, membranes were incubated overnight at 4°C with primary antibodies against phosphorylated VEGFR-2 (Tyr 996; sc-16629-R, 1 : 200, Santa Cruz Biotechnology, Dallas, TX, USA), total forms of VEGFR-2 (ab131441, 1 : 300, Abcam), and b-actin (4967, 1 : 500, Cell Signaling Technology, Danvers, MA, USA). The membranes were then incubated with horseradish peroxidaseconjugated secondary antibody (1 : 10 000, Cell Signaling Technology) for 1 h at 24°C. The blots were developed in enhanced chemiluminescence reagents (Thermo Scientific) and exposed to X-ray film. Signals were quantified with Quantity One software 4.62 (Bio-Rad).
Statistical analysis
The number of wells with each treatment was balanced within each cell culture experiment. The person performing cell counts was blinded to treatment, whereas the person performing biochemical assays was not blinded to treatment. Work by others indicated a coefficient of variation of approximately 10% in VEGF levels measured by ELISA in astrocyte media after anoxia (SchmidBrunclik et al. 2008) . Based on this coefficient of variation, we chose a sample size of 4 independent experiments to provide 80% power for detecting 30% relative changes in VEGF with p < 0.05. All data were analyzed by analysis of variance. If the F-value was significant at the 0.05 level, individual mean values were compared with the Holm-Sidak procedure for multiple comparisons. The primary comparisons were to a normoxic control group and to an OGD plus vehicle group. In cases where tests for normality and homogeneity of variance failed, a logarithmic transformation was applied to the data, which then passed these tests. Data are presented as means AE SD.
Results
Effect of sEH inhibitor on astrocyte viability after OGD Triple-labeling with GFAP, propidium iodide (PI), and DAPI was used to identify the effect of sEH inhibitors on astrocyte viability after OGD (Fig. 1) . Compared with viability in the normoxia group, OGD with vehicle caused a significant reduction in viable astrocytes (95.5 AE 0.3% vs. 71.9 AE 2.5%, p < 0.01). Administration of either TPPU or t-AUCB (100 lM) after OGD led to significant improvements in cell viability (86.3 AE 1.8% and 87.3 AE 3.4%, respectively), thereby indicating that sEH inhibitors have a protective effect against OGD in astrocytes (Fig. 1) .
Inhibitors of sEH help restore astrocyte release of EETs after OGD The concentration of the four regioisomers of EETs was measured in the astrocyte medium 24 h after OGD. Relative to normoxic controls, OGD reduced the levels of all four EET regioisomers by two orders of magnitude (Fig. 2) . Addition of TPPU or t-AUCB largely preserved the levels of the regioisomers after OGD, although the levels remained significantly less than those in the normoxic controls for 5,6-EET, 8,9-EET and 11,12-EET. Thus, the sEH inhibitors achieved the intended effect of increasing EETs after OGD.
Inhibitors of sEH increase astrocyte VEGF secretion and expression after OGD ELISA analysis showed that OGD with vehicle led to a small, but significant, 16% increase in VEGF secreted from primary astrocytes into the media (Fig. 3a) compared with levels in the normoxia group. Administration of TPPU or t-AUCB after OGD significantly and dose-dependently increased astrocyte VEGF secretion into the media and cell protein expression (Fig. 3a and b) . For example, 1 lM TPPU increased VEGF in the medium by 50%, whereas 100 lM increased VEGF by 300% (Fig. 3a) . In the absence of OGD, 100 lM TPPU and t-AUCB increased VEGF in the media by 33% and 25%, respectively. These increases were significantly less than the corresponding levels attained with treatment after OGD. Thus, the sEH inhibitors exert a synergistic effect on VEGF secretion when combined with OGD and reoxygenation.
To determine whether the augmentation of VEGF release by sEH inhibitors required the actions of EETs exclusively, we treated wells of OGD astrocytes with a combination of TPPU (100 lM) or t-AUCB (100 lM) and the EET antagonist 14,15-EEZE (100 lM) during the 48 h of reoxygenation. As in the previous experiments, after 6 h of OGD, treatment with 100 lM of TPPU or t-AUCB for 48 h of reoxygenation led to corresponding increases in secreted VEGF of 260% or 120% when compared with OGD/vehicletreated astrocytes. These increases were completely suppressed by 14,15-EEZE application (Fig. 3c) , thereby indicating that the effect of the inhibitors could be attributed to the actions of EETs.
To evaluate whether administration of exogenous EETs recapitulate the effect of the sEH inhibitors, we added 14,15-EET over a concentration range of 0.1-30 lM to the astrocyte medium after OGD. Concentration-dependent increases were observed over the 1-30 lM range of 14,15-EET (Fig. 3d) . Furthermore, addition of 30-100 lM TPPU to the lowest effective 14,15-EET concentration of 1 lM significantly augmented the VEGF response.
Enhanced activation of neuronal VEGF receptor-2 and neuronal survival Because we found that the sEH inhibitors can augment astrocyte VEGF secretion and expression after OGD, we wanted to investigate whether this augmentation would subsequently protect neurons from oxygen and glucose restoration after OGD. For this reason, we did co-culture 
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Astrocytes were labeled with glial fibrillary acidic protein (GFAP) (green), propidium iodide (red), and DAPI (blue). (e) The percentage of viable astrocytes was calculated from the percentage of DAPIstained nuclei that were not co-stained with propidium iodide. Three different fields of view on each coverslip were counted and averaged. Data are shown as mean AE SD; n = 3 independent experiments. *p < 0.05 versus normoxia; #p < 0.05 versus OGD + vehicle. Scale bars = 50 lm on images obtained with a 20 9 lens.
experiments. Primary neurons were subjected to 1-h OGD, which is sufficient to produce moderate levels of cell death. These cells were then exposed to conditioned medium from OGD astrocytes that had been treated with vehicle or an sEH inhibitor (100 lM TPPU or t-AUCB). However, for the medium to be compatible with neurons, the astrocytes were transferred to fresh NB/B27 medium for 24 h before exposure of the neurons to the astrocyte medium. Because the replacement medium did not contain sEH inhibitors, we determined whether the increased release of VEGF into the new astrocyte medium would be sustained. As shown in Fig. 4a , the increase in the VEGF concentration 24 h after removal of TPPU or t-AUCB from OGD-treated astrocytes (77.9 AE 10.5 or 47.8 AE 6.8 pg/mL, respectively) was significantly higher than after removal of vehicle from OGDtreated astrocytes (22.5 AE 2.1 pg/mL, p < 0.05; Fig. 4a) . These values were similar to those obtained in the previous experiments in which the medium was not replaced with NB/ B27 medium and the sEH inhibitors were still present. This observation indicates that astrocytes previously exposed to OGD and sEH inhibitor can continue secreting VEGF and at a high concentration despite medium replacement and sEH inhibitor removal. This finding may also indicate that these sEH inhibitors have long enzyme residence times that lengthen their effects (Lee et al. 2014) . Because the OGD neurons were exposed to the astrocyte replacement medium for an additional 24 h, we further evaluated the time course of the VEGF concentration after replacing the astrocyte medium with NB/B27. We found that the VEGF concentration remained elevated for at least 48 h after removal of 100 lM TPPU compared to the control group previously treated with vehicle (Fig. 4b ). This 48-h time point for astrocytes corresponds to 24 h after the neurons underwent OGD.
Activation of VEGFR-2 is associated with phosphorylation at Tyr 996. Western blotting with an antibody selective for Tyr 996 showed that phosphorylated VEGFR-2 was significantly increased 24 h after OGD in neurons that were co-cultured with conditioned medium from TPPU-or t-AUCB-treated OGD astrocytes compared with those cocultured with conditioned medium from vehicle-treated OGD astrocytes (Fig. 5) .
Neuronal cell death was assessed by TUNEL staining of DAPI-demarcated nuclei (Fig. 6) . As expected, compared to untreated, normoxic controls, the number of TUNELpositive neurons increased when OGD neurons were cocultured with astrocytes previously treated with vehicle after OGD. The increase in TUNEL-positive neurons was attenuated when the astrocytes had been treated with TPPU or t-AUCB after OGD (Fig. 6 ). MAP2 staining also suggested that treatment with the sEH inhibitors reduced swelling of the cell body and maintained fine processes of neurons (Fig. 6) .
Phosphorylation of Akt
Because VEGFR-2 activation can increase phosphorylation of Akt, which promotes neuronal survival (Hao and Rockwell 2013) , we compared the Akt phosphorylation state after exposure of neurons to OGD followed by astrocyte conditioned media. As shown in Fig. 7 , the phosphorylation of Akt (p-Akt) in OGD neurons was significantly greater when the neurons were co-cultured with TPPU-or t-AUCB-treated OGD astrocytes than when co-cultured with vehicle-treated OGD astrocytes. This increase was blocked by treatment of the neurons with the VEGFR-2 antagonist SU1498. These results suggest that the neuronal pro-survival signaling of astrocyte medium previously conditioned with TPPU or t-AUCB requires VEGFR-2 activation.
Discussion
The major findings of this study are that (i) inhibition of sEH in astrocytes after 6-h OGD increases survival of astrocytes in association with an increase in EETs levels, (ii) inhibition of sEH in astrocytes after OGD produces a sustained release of VEGF, (iii) this increase is blocked by an EET antagonist and recapitulated by administration of exogenous EETs, (iv) medium from astrocyte culture treated with OGD and sEH inhibition augments pro-survival p-Akt signaling in neurons after OGD by a mechanism that requires VEGF receptor-2 activation, and (v) astrocyte medium conditioned by OGD and sEH inhibition improves survival of neurons subjected to OGD.
Inhibition of sEH is known to reduce infarct volume in experimental stroke (Zhang et al. 2007; Shaik et al. 2013) . Astrocytes, which are more resistant than neurons to ischemic injury, may help support the viability of neurons. Application of EETs to cultured astrocytes has been reported to improve survival from OGD (Li et al. 2012; Yuan et al. 2016) and to protect astrocyte mitochondria from b-amyloid toxicity (Sarkar et al. 2014 ). We used 6 h of OGD to produce a stress from which the majority of astrocytes could survive. In this condition, the sEH inhibitor provided substantial reduction in astrocyte cell death. This observation supports the concept that EETs have a protective effect in astrocytes.
Previous work from our group showed that the EET antagonist 14,15-EEZE reduces acute hypoxia-induced cerebral vasodilation in vivo (Liu et al. 2015) and that hypoxia without glucose deprivation increases the formation of EETs by cultured astrocytes (Yamaura et al. 2006) . Thus, we anticipated that OGD would increase the level of EETs. In contrast, we observed a profound reduction of EETs 24 h after OGD. Possible explanations for the low EET levels include the greater insult associated with combining hypoxia with glucose deprivation and with the relatively long 6-h duration of the OGD. Nevertheless, administration of TPPU or t-AUCB after OGD nearly restored the levels of all EET regioisomers. This restoration is presumably attributable to inhibition of the hydrolysis of EETs. Because EETs can open calcium-sensitive K + channels in astrocytes (Yamaura et al. 2006 ) and protect astrocytes (Li et al. 2012) , improved physiological function of astrocytes afforded by EETs may have helped preserve the astrocyte synthetic capacity for EETs and thereby further augment the restoration of EETs after OGD. Because we used both TPPU and t-AUCB in all experiments and obtained similar results, it is less likely that the effects of the chemicals are as a result of nonspecific effects but more likely that they are acting as sEH inhibitors.
Astrocytes are a source of several neurotrophic factors. A recent report found that addition of 14,15-EET to astrocytes after OGD increased brain-derived neurotrophic factor (BDNF) mRNA approximately 20% in association with an increase in viable astrocytes; glial cell line-derived neurotrophic factor, nerve growth factor, and neurotrophin-4/5 mRNA were unaffected by 14-15-EET (Yuan et al. 2016) . Fig. 4 Increased vascular endothelial growth factor (VEGF) persists after removal of soluble epoxide hydrolase (sEH) inhibitor. (a) VEGF measurements were made 24 h after switching the astrocyte medium from DMEM/F-12 to NB/B27. The switch in medium occurred after astrocytes were exposed to 6-h oxygen-glucose deprivation (OGD) and 48-h reoxygenation with vehicle, 100 lM 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU), or 100 lM trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB). The data show that VEGF remained elevated 24 h after removal of sEH inhibitors, corresponding to the time at which co-culture with neurons was started. Values are mean AE SD; n = 4 independent experiments; *p < 0.01 versus vehicle-treated OGD astrocytes. (b) Time course of VEGF concentration in the astrocyte medium over 48 h after switching the medium in astrocytes previously exposed to OGD and 48-h reoxygenation with vehicle or 100 lM TPPU. Values are mean AE SD; n = 3 independent experiments. *p < 0.05 versus vehicle-treated OGD + vehicle. Note that VEGF remained elevated at 48 h, corresponding to the time when co-culture with neurons ended. Thus, EETs exert some degree of specificity in regulating neurotrophic factors in astrocytes. However, this study did not examine VEGF. We focused on astrocyte release of VEGF because astrocytes release VEGF under hypoxic conditions (Sinor et al. 1998; Schmid-Brunclik et al. 2008) , sEH inhibitors can promote VEGF release in other tissue (Sander et al. 2011; Panigrahy et al. 2013; Xu et al. 2013) , and VEGF can exert pro-survival effects in neurons (Sanchez et al. 2010; Hao and Rockwell 2013) . Here, we found that administration of sEH inhibitors without exposure to OGD produced 25-33% increases in VEGF in the astrocyte medium. These results indicate that the action of EETs on VEGF expression does not require hypoxia. However, because the VEGF gene has a hypoxic response element, we expected that VEGF would be substantially up-regulated after OGD. Twenty-four hours after OGD, we detected only a modest 16% increase in VEGF protein in the cell lysate and medium of vehicle-treated astrocytes. Importantly, addition of TPPU after OGD markedly amplified this increase in VEGF as high as threefold, and addition of t-AUCB increased VEGF by as much as twofold. Interestingly, the magnitude of this effect on VEGF is greater than the approximately 50% augmentation of BDNF protein by 14,15-EET administration reported by others (Yuan et al. 2016) . Because the magnitude of this amplification is much greater than the relative increase in astrocyte cell survival, this amplification likely reflects a strong synergistic interaction of epoxides with hypoxia on VEGF expression, rather than simply an increase in the number of surviving astrocytes. The mechanism of this interaction remains to be determined. Induction of VEGF through a peroxisomeproliferator-activated receptor-c coactivator-1a mechanism that is independent of hypoxia inducible factors has been described (Arany et al. 2008) . Whether EETs act through hypoxia inducible factors or independent of them in astrocytes remains to be determined. Nevertheless, the effect of TPPU and t-AUCB on VEGF secretion into the medium persisted 48 h after removal of the sEH inhibitors. This persistence suggests an effect on VEGF gene induction rather than an effect on VEGF transport or metabolism. The persistence effect may also be as a result of the fact that the inhibitors used in this study have long enzyme residence times, which could prolong their biological effect (Lee et al. 2014) . Several epoxides of long-chain fatty acids are hydrolyzed by sEH. The observations that the EET antagonist 14,15-EEZE blocked the augmentation of VEGF secretion by TPPU and t-AUCB suggest that the action of EETs, rather than other epoxides, is primarily responsible for this effect of sEH inhibition. Further support for the role of EETs is derived from the VEGF response data to different concentrations of 14,15-EET. A concentration of 0.1 lM 14,15-EET, which exceeds the concentration measured after OGD with vehicle treatment (Fig. 2) , failed to increase VEGF (Fig. 3d) . In contrast, concentrations in the range of 1-10 lM, which were achieved after OGD with TPPU and t-AUCB treatment, significantly increased VEGF (Fig. 3d) and further increases could be obtained by combining 1 lM 14,15-EET with 30 or 100 lM TPPU (Fig. 3d) . Thus, the concentration of EETs measured with the different treatments is internally consistent with the concentration of EETs required to increase VEGF release.
In the transwell experiments, neurons were removed from OGD and, immediately upon reoxygenation, were cultured with the conditioned astrocyte medium. Exposure of the neurons to the medium from astrocytes treated with either of the sEH inhibitors increased neuronal VEGFR-2 phosphorylation and Akt phosphorylation and decreased neuronal TUNEL staining. The increased VEGFR-2 phosphorylation reflects increased receptor activation and indicates that the VEGF released by astrocytes is sufficient to activate neuronal receptors despite dilution by the relatively large extracellular space in cell culture. Phosphorylation of Akt promotes antiapoptotic signaling, and the decrease in TUNEL signaling indicates decreased neuronal cell death. The increase in Akt phosphorylation was blocked by addition of the VEGFR-2 antagonist SU1498 to the neuronal medium after OGD. Thus, the beneficial effect of the sEH inhibitor-conditioned astrocyte medium on this pro-survival pathway in neurons appears to require activation of neuronal VEGFR-2.
A limitation of this study is that we did not investigate whether the VEGFR-2 antagonist completely blocked the beneficial effect on TUNEL staining of the astrocyte medium conditioned with sEH inhibitors. Although we did not examine whether VEGFR-1 also contributes to this neuronal protection, this possibility seems unlikely because VEGFR-2 is the primary receptor required for VEGF's antiapoptotic effect in neurons (Hao and Rockwell 2013) . It should also be noted that we used different durations of OGD for neurons and astrocytes because of their differing vulnerability. When the neurons were reoxygenated and immediately exposed to the astrocyte conditioned medium, 3 days had elapsed since the astrocytes had been exposed to OGD. Our intention was to allow time for the astrocyte VEGF secretion to occur and then to wash out the sEH inhibitor so that it would not have a direct effect on neurons. We reasoned that an early intervention to manipulate EETs could have a prolonged effect on trophic factor release that would ameliorate secondary neuronal death and possibly promote neurorepair.
Despite these artificial conditions, these experiments provide a proof of concept for one of the potential mechanisms by which astrocytes can protect neurons after reoxygenation from ischemia. Astrocytes can release growth Neurons were subjected to 1-h oxygen-glucose deprivation (OGD) and then cultured in NB/B27 alone or co-cultured with astrocytes previously stimulated with OGD plus vehicle (0.1% DMSO) or 100 lM TPPU or t-AUCB. During the 24 h of co-culture, some neurons were also treated with the VEGFR-2 antagonist SU1498 (10 lM). Neuronal lysates in each condition were analyzed by Western blotting for detection of phosphorylated Akt (p-Akt) and total Akt. b-actin served as the loading control. Levels of p-Akt were normalized to total Akt and then quantified relative to the OGD neurons without astrocyte co-culture (100%). Data are shown as mean AE SD; n = 4 independent experiments. *p < 0.01 versus OGD neurons co-cultured with vehicle-treated OGD astrocytes; # p < 0.05 versus OGD neurons co-cultured with TPPU-treated astrocytes; † p < 0.05 versus OGD neurons co-cultured with t-AUCB-treated astrocytes.
factors other than VEGF and some of these may also provide acute neuroprotection or help to restore function of the remaining neurons after an ischemic event. For example, 14,15-EET can promote expression of BDNF after OGD, and interfering with astrocyte BDNF-TrkB signaling attenuated the 14,15-EET protection of astrocytes and neurons (Yuan et al. 2016) . Thus, there might be convergence of BDNF and VEGF signaling in promoting neuronal survival. In addition, our experiments do not exclude the possibility that, in vivo, EETs released from astrocytes might act directly on neurons to provide protection. Hence, other EET-dependent orindependent neuroprotective mechanisms may exist in astrocytes besides those demonstrated for astrocyte VEGF release in the present model. Therefore, promoting EET bioavailability through inhibition of sEH could be one strategy for leveraging astrocyte-based neuroprotection and possibly neurorepair.
